New technologies for target discovery in neuropsychiatric disorders (2022-2027)
Neuropsychiatric disorders (NPDs) are major causes of human suffering, loss of lives and productivity all over the world. Currently used pharmacotherapies against NPDs have low efficacy and specificity and were introduced 50-100 years ago mainly based on accidental findings. However, recent molecular genetic studies have revealed strongly associated genetic loci, enriched in brain pathways and proteins, and possible new therapeutic targets for NPDs. Moreover, revolutionary new technological breakthroughs have been reported in computational and experimental molecular life sciences. These technologies will be refined, applied and combined in the NeuroConvergence project for systematic identification and testing of new molecular targets in the treatment of NPDs.
More information can be found in the NFR project bank.
Group members involved
- Ammar Malik (postdoc, 2022-2025)
Project partners
- Jan Haavik (project manager)
- Petri Kursula
- Knut Teigen
- Tetyana Zayats
- Stephen Faraone
- Manfred Jung
- Andreas Reif
Project updates
| Date | Title |
|---|---|
| Oct 22, 2023 | Use of big data and machine learning algorithms in neurodevelopmental disorders review |
| Aug 22, 2023 | Causal inference in drug discovery review |
| Sep 30, 2022 | Causal inference in drug discovery preprint |
| Sep 16, 2022 | Ammar and Adriaan present at ECCB |
| Sep 16, 2022 | Ammar presents at WCPG |
| Aug 25, 2022 | Congrats Ammar! |
| Apr 6, 2022 | Postdoc position available |